Influence of acarbose on post-prandial insulin requirements in patients with Type 1 diabetes

Diabetes, Nutrition and Metabolism - Clinical and Experimental

Volumn 13, Issue 1, 2000, Pages 7-12

  Juntti Berggren, L ^a,d   Pigon, J ^b   Hellstrom P ^b   Holst, J J ^c   Efendic, S ^a  

^a Unit for Diabetes and Endocrinology   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Acarbose; Insulin; Type 1 diabetes

Indexed keywords

ACARBOSE; GASTRIC INHIBITORY POLYPEPTIDE; GASTROINTESTINAL POLYPEPTIDE; GLUCAGON; GLUCOSE; INSULIN; PARACETAMOL; TRIACYLGLYCEROL;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; FEMALE; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LIPID BLOOD LEVEL; MALE; MEAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH EMPTYING;

ACARBOSE; ADULT; BLOOD GLUCOSE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 1; DOUBLE-BLIND METHOD; FEMALE; GASTRIC EMPTYING; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; PEPTIDE FRAGMENTS; POSTPRANDIAL PERIOD; PROTEIN PRECURSORS; TRIGLYCERIDES;

EID: 0034034573     PISSN: 03943402     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Lowe L.P., Liu K., Greenland P., Metzger B.E., Dyer A.R., Stanler J.: Diabetes, asymptomatic hyperglycemia and 22-year mortality in black and white men. The Chicago Heart Association Detection Project in Industry Study. Diabetes Care 20: 163-169, 1997.
2. Donahue R.P., Abbott R.D., Reed D.M., Yano K.: Post challenge glucose concentration and coronary heart disease in men of Japanese ancestry. Honolulu Heart Program. Diabetes 36: 689-692, 1987.
3. Barrett-Connor E., Ferrara A.: Isolated postchallenge hyperglycemia and the risk of fatal cardiovascular disease in older women and men. The Rancho Bernardo study. Diabetes Care 21: 1236-1239, 1998.
4. Hanefeld M., Koehler C., Schaper F., Fuecker K., Henkel E., Temelkova-Kurktschiev T.: Postprandial plasma glucose is an independent risk factor for increased carotid intima-media thickness in non-diabetic individuals. Atherosclerosis 144: 229-235, 1999 (in press).
5. Kawamori R.: Asymptomatic hyperglycaemia and early at-h erosclerotic changes. Diabetes Res. Clin. Pract. 40 (Suppl.): S35-S42, 1998.
6. Escobar-Jimenez F., de Leiva A., Pinon F., Soler J., Tebar J., Sancho M.A., Herrera-Pombo J.L., Pallardo L.F., Vazquez J.A., de la Calle H.: Clinical efficacy and tolerance of acarbose in the treatment of insulin-dependent diabetic patients. Med. Clin. 100: 488-491, 1993.
7. Marena S., Tagliaferro V., Cavallero G., Pagani A., Montegrosso G., Bianchi W., Zaccarini P., Pagano G.: Double-blind crossover study of acarbose in type 1 diabetic patients. Diabet. Med. 8: 674-678, 1991.
8. Lecavlier L., Hamet P., Chiasson J.L.: The effects of sucrose meal on insulin requirement in IDDM and its modulation by acarbose. Diabete Metab. 12: 156-161, 1986.
9. Dimitriadis G., Karaiskos C., Raptis S.: Effects of prolonged (6 months) alpha glucosidase inhibition on blood glucose control and insulin requirements in patients with insulin-dependent diabetes. Horm. Metab. Res. 18: 253-255, 1986.
10. Coniff R.F., Shapiro J.A., Robbins D., Kleinfield R., Seaton T.B., Beisswenger P., McGill J.B.: Reductions of glycosylated haemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. A placebo-controlled dose comparison study. Diabetes Care 18: 817-824, 1995.
11. Hoffmann J., Spengler M.: Efficacy of 24 week monotherapy with acarbose, gliblenclamide or placebo in NIDDM patients: the Essen study. Diabetes Care 17: 561-566, 1994.
12. Hoffmann J., Spengler M.: Efficacy of 24 week monotherapy with acarbose, metformin or placebo in dietary treated NIDDM patients: the Essen II study. Am. J. Med. 103: 483-490, 1997.
13. Mertes G.: Efficacy and safety of acarbose in the treatment of type II diabetes: data from a 2 year surveillance study. Diab. Res. Clin. Prac. 40: 63-70, 1998.
14. Hotta N., Kakuta H., Sano T., Matsumae H., Yamada H., Kitazawa S., Sakamoto N.: Long-term effect of acarbose on glycaemic control in non-insulin-dependent mellitus: a placebo-controlled double-blind study. Diabet. Med. 10: 134-138, 1993.
15. Krarup T., Madsbad S., Moody A.J., Regeur L., Faber O.K., Holst J.J., Sestoft L.: Diminished gastric inhibitory polypeptide (GIP) response to a meal in newly diagnosed type I (insulin dependent) diabetics. J. Clin. Endocrinol. Metab. 56: 1306-1312, 1983.
16. Holst J.J.: Evidence that enteroglucagon (II) is identical with the C-terminal sequence (residues 33-39) of glicentin. Biochem. J. 207: 381-388, 1982.
17. Orskov C., Rabenhoj L., Wettergren A., Kofod H., Holst J.J.: Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide-I in humans. Diabetes 43: 535-539, 1994.
18. Ferrannini E.: The theoretical bases of indirect calorimetry: a review. Metab. Clin. Exp. 37: 287-301, 1988.
19. Heading R.C., Nimmo J., Prescott L.F., Tothill P.: The dependence of paracetamol absorption on the rate of gastric emptying. Br. J. Pharmacol. 47: 415-421, 1973.
20. Gutniak M.K., Juntti-Berggren L., Hellström P.M., Guenifi A., Holst J.J., Efendic S.: Glucagon-like peptide 1 enhances the insulinotropic effect of glibenclamide in NIDDM patients and in the perifused rat pancreas. Diabetes Care 19: 857-863, 1996.
21. Hollander P., Pi-Sunyer X., Coniff R.F.: Acarbose in the treatment of type 1 diabetes. Diabetes Care 20: 248-253, 1997.
22. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329: 683-689, 1993
23. Raganath L., Norris F., Morgan L., Wright J., Marks V.: Delayed gastric emptying occurs following acarbose administration and is a further mechanism for its anti-hyperglycaemic effect. Diabet. Med. 15: 120-124, 1998.
24. Seifarth C., Bergmann J., Holst J.J., Ritzel R., Schmiegel W., Nauck M.A.: Prolonged and enhanced secretion of glucagon-like peptide 1 (7-36 amide) after oral sucrose due to alpha-glucosidase inhibition (acarbose) in type 2 diabetic patients. Diabet. Med. 15: 485-491, 1998.